4-chloro-6,7-dihydro-2-methylpyrimido<5,4-b><1,4>oxazin-7(8H)-one | 38953-47-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-chloro-6,7-dihydro-2-methylpyrimido<5,4-b><1,4>oxazin-7(8H)-one
• 英文别名: 4-chloro-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one；4-chloro-2-methyl-8H-pyrimido[5,4-b][1,4]oxazin-7-one；4-chloro-6,7-dihydro-2-methyl-8H-pyrimido[5,4-b][1,4]oxazin-7-one；4-Chloro-2-methyl-8H-pyrimido[5,4-b][1,4]oxazin-7-one
• CAS: 38953-47-8
• 化学式: C₇H₆ClN₃O₂
• 分子量: 199.597
• InChiKey: RTTOTCBXASAAPS-UHFFFAOYSA-N

物化性质

• 熔点：
  175.5-176 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  401.1±45.0 °C(Predicted)
• 密度：
  1.483±0.06 g/cm3(Predicted)
• 溶解度：
  >29.9 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-6,7-dihydro-2-methylpyrimido<5,4-b><1,4>oxazin-7(8H)-one 在 一水合肼 作用下， 以 正丁醇 为溶剂， 反应 0.5h， 以56%的产率得到4-Hydrazino-2-methyl-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-7-one
  参考文献：
  名称：

  含嘧啶并[5，4- b ] [1，4]恶嗪骨架的新三环系统的合成

  摘要：

  衍生物的合成4和6两种新型三环的环系统，第1，2，2,4-三唑并[3,4的Ç ]嘧啶并[5，4- b ] - [1,4]恶嗪和咪唑并[1,2- Ç分别描述了] pyrimido [5,4- b ] [1,4]恶嗪。尽管母体嘧啶并[ 5,4- b ]恶嗪具有正性变力活性，但三环化合物实际上是无活性的。

  DOI：

  10.1002/jhet.5570260341
• 作为产物：
  描述：

  (4-amino-6-chloro-2-methyl-pyrimidin-5-yloxy)-acetic acid 在 乙酸酐 作用下， 生成 4-chloro-6,7-dihydro-2-methylpyrimido<5,4-b><1,4>oxazin-7(8H)-one
  参考文献：
  名称：

  缩合嘧啶，吡嗪和吡啶体系的研究

  摘要：

  DOI：

  10.1007/bf00470116

文献信息

• Pyrimido[5,4-B][1,4]oxazine derivatives and pharmaceutical compositions
  申请人：Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt

  公开号：US04748175A1

  公开（公告）日：1988-05-31

  The invention relates to novel pyrimido [5,4-b][1,4]oxazine derivatives of the formula (I), and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the formula (I) ##STR1## wherein R.sup.1 stands for a C.sub.1-4 alkyl group; R.sup.2 stands for hydrogen or halogen or an azido group or an --NR.sup.5 R.sup.6 group, wherein R.sup.5 represents hydrogen or a benzyl group, or a C.sub.1-4 alkyl group unsubstituted or substituted by a hydroxyl group, R.sup.6 stands for hydrogen, an amino group, a C.sub.3-6 cycloalkyl group, a straight or branched-chain C.sub.1-4 alkyl group optionally substituted by a hydroxyl, mercapto, aminocarbonyl, furyl, 2-benzo[1,4]dioxanyl, di(C.sub.1-4 alkyl)amino group or by a phenyl or phenoxy group optionally mono- or polysubstituted by halogen or C.sub.1-4 alkoxy group (s) or by a 6-membered, saturated nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C.sub.1-4 alkyl or benzyl group; further NR.sup.5 R.sup.6 may also represents a 6-membered, saturated, nitrogen-containing heterocycle optionally containing an additional nitrogen or oxygen atom and optionally substituted by a C.sub.2-4 alkoxycarbonyl or C.sub.1-4 hydroxyalkyl group; R.sup.3 and R.sup.4 are the same or different and stand for hydrogen or a C.sub.1-4 alkyl group; R.sup.9 stands for hydrogen or a C.sub.1-4 alkyl group unsubstituted or monosubstituted by an oxo, cyano, aminocarbonyl, C.sub.2-5 alkoxycarbonyl, pyridiyl, morpholinocarbonyl, or phenyl group or mono- or polysubstituted by OH group(s), with the proviso that R.sup.2 is different from chlorine, 4-morpholinyl and piperidyl group when R.sup.9 stands for hydrogen; or R.sup.2 is different from chlorine and 4-morpholinyl group when R.sup.9 stands for a methyl or benzyl group. The compounds of the formula (I) are capable to increase the myocardial contractile force (the performance of the failing heart) and the coronary blood flow, thus they can therapeutically be used for the treatment of the chronic heart failure and coronary disturbances.

  该发明涉及一种新型嘧啶并[5,4-b][1,4]噁嗪衍生物的公式(I)，以及其酸盐，含有它们的药物组合物和其制备方法。在公式(I)中，其中R^1代表一个C.sub.1-4烷基基团；R^2代表氢或卤素或偶氮基或--NR^5R^6基团，其中R^5代表氢或苄基团，或一个未取代或取代的C.sub.1-4烷基基团，R^6代表氢，氨基，C.sub.3-6环烷基基团，直链或支链的C.sub.1-4烷基基团，可选地取代羟基，巯基，氨基羰基，呋喃基，2-苯并[1,4]二氧杂基，二(C.sub.1-4烷基)氨基基团或由卤素或C.sub.1-4烷氧基基团单取代或多取代的苯基或苯氧基，或由含氮的饱和6-成员杂环取代的苯基或苯氧基；进一步NR^5R^6也可以表示含有额外氮或氧原子并可选地取代C.sub.1-4烷基或苄基的含氮饱和6-成员杂环；R^3和R^4相同或不同，代表氢或C.sub.1-4烷基基团；R^9代表氢或未取代或单取代的C.sub.1-4烷基基团，氧代脂肪酰基，氰基，氨基羰基，C.sub.2-5烷氧基羰基，吡啶基，吗啉基羰基或苯基或由OH基取代的单取代或多取代的羟基，条件是当R^9代表氢时，R^2与氯，4-吗啉基和哌啶基不同；或当R^9代表甲基或苄基时，R^2与氯和4-吗啉基不同。公式(I)化合物能够增加心肌收缩力（衰竭心脏的性能）和冠状血流，因此它们可以用于治疗慢性心力衰竭和冠状动脉障碍。
• [EN] TRICYCLIC NITROGEN COMPOUNDS USED AS ANTIBACTERIALS<br/>[FR] COMPOSÉS AZOTÉS TRICYCLIQUES UTILISÉS COMME AGENTS ANTIBACTÉRIENS
  申请人：GLAXO GROUP LTD

  公开号：WO2010043714A1

  公开（公告）日：2010-04-22

  Tricyclic nitrogen containing compounds (I) and their use as antibacterials.

  三环氮含有化合物（I）及其作为抗菌剂的用途。
• Synthesis and cardiotonic activity of pyrimido[5,4-<i>b</i>][1,4]oxazinones and 1,4-dioxino[2,3-<i>d</i>]pyrimidines
  作者：Péter Mátyus、Nándor Makk、Anikó Tegdes、Judit Kosáry、Endre Kasztreiner、Benjamin Podányi、György Rabloczky、Mária Kiirthy

  DOI：10.1002/jhet.5570270207

  日期：1990.2

  The new pyrimido[5,4-b][1,4]oxazinones 4a-c and 6a,b, 7a,c were obtained from 6-amino-2,3-dimethyl-4(3H)-pyrimidone (1) and 4-substituted pyrimido[5,4–6][1,4]oxazinones 5, 7a, respectively, while derivatives 8a-e of the novel ring system 1,4-dioxino[2,3-d]pyrimidine were prepared starting from 2b.

  从6-氨基-2,3-二甲基-4（3 H）-嘧啶酮（1）获得了新的嘧啶并[5,4- b ] [1,4]恶嗪酮4a-c和6a，b，7a，c。和4-取代的嘧啶并[5,4-b] [1,4] oxazinones 5，图7A，分别，而新颖的环系统1,4-二恶英并[2,3-的衍生物8A-E d ]嘧啶开始制备从2b开始。
• [EN] TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION<br/>[FR] COMPOSÉS CONTENANT DE L'AZOTE TRICYCLIQUE POUR LE TRAITEMENT DE L'INFECTION À NEISSERIA GONORRHOEAE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016027249A1

  公开（公告）日：2016-02-25

  The present invention relates to methods for treating Neisseria gonorrhoeae infection which comprises administering to a subject in need thereof novel Tricyclic nitrogen containing compounds and corresponding pharmaceutical compositions as described herein.

  本发明涉及一种治疗淋病奈瑟氏菌感染的方法，包括向需要该方法的受试者施用本文所述的新型三环氮含量化合物及相应的药物组成。
• Triazolo[1,5-c]pyrimido[1,4]-azines as bronchodilators
  申请人：Riker Laboratories, Inc.

  公开号：US05166343A1

  公开（公告）日：1992-11-24

  Substituted 1,2,4-triazolo[1,5-c]pyrimido[1,4]azines have been found to have potent bronchodilator activity. Pharmacological methods for inducing bronchodilation using such compounds, pharmaceutical compositions containing such compounds, and synthetic intermediates for preparing such compounds are also described.

  已发现替代的1,2,4-三唑并[1,5-c]嘧啶并[1,4]嗪具有强效的支气管扩张活性。本文还描述了使用这些化合物诱导支气管扩张的药理学方法，含有这些化合物的制药组合物以及制备这些化合物的合成中间体。